BIO’s Tom DiLenge Testifies on Biotechnology Innovation Ecosystem before House E&C #SubHealth

At a hearing today held by the House Energy and Commerce Subcommittee on Health on “Examining the Drug Supply Chain,” BIO President for Advocacy, Law and Public Policy Tom DiLenge testified on the innovative biopharmaceutical development and delivery system and its enormous contributions to patient health and the U.S. economy.
In his testimony, DiLenge cited the factors that have allowed American companies to take a leading role in biopharmaceutical innovation, responsible for nearly